In the wake of Roche’s recent failure with the cancer medication tiragolumab, the company announced on Thursday that its Alzheimer’s drug crenezumab was unable to halt or prevent cognitive decline in patients who possessed a particular genetic mutation that leads to the disease’s onset at an earlier age. This information was gleaned from research.
According to a statement released by the pharmaceutical company that makes Crenezumab, the drug’s co-primary objectives of assessing cognitive capacity and episodic memory function did not reveal statistically relevant therapeutic improvements.
Roche decided to conduct the Alzheimer’s Prevention Initiative (API) Autosomal Dominant Alzheimer’s Disease (ADAD) Colombia Trial to determine whether or not crenezumab can slow the progression of Alzheimer’s disease or even prevent it entirely in cognitively normal individuals who carry a particular genetic mutation.
The Basel-based business had previously encountered a significant obstacle with an unproven treatment for cancer that was being evaluated during the month before this one.
In the wake of Roche’s recent failure with the cancer medication tiragolumab, the company announced on Thursday that its Alzheimer’s drug crenezumab was unable to halt or prevent cognitive decline in patients who possessed a particular genetic mutation that leads to the disease’s onset at an earlier age. This information was gleaned from research.
According to a statement released by the pharmaceutical company that makes Crenezumab, the drug’s co-primary objectives of assessing cognitive capacity and episodic memory function did not reveal statistically relevant therapeutic improvements.
Roche decided to conduct the Alzheimer’s Prevention Initiative (API) Autosomal Dominant Alzheimer’s Disease (ADAD) Colombia Trial to determine whether or not crenezumab can slow the progression of Alzheimer’s disease or even prevent it entirely in cognitively normal individuals who carry a particular genetic mutation.
The Basel-based business had previously encountered a significant obstacle with an unproven treatment for cancer that was being evaluated during the month before this one.
An interim analysis of an ongoing clinical trial that was released in May found that the investigational medication TIRAGOLUMAB, which is manufactured by Roche, did not reduce the progression of disease in newly diagnosed patients with advanced non-small-cell lung cancer (NSCLC) in combination with Roche’s authorized PD-L1 immunotherapy Tecentriq. This information was gleaned from the ongoing trial.
